NYSEAMERICAN:PTN - Palatin Technologies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.00
  • Forecasted Upside: 506.06 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.50
▼ -0.02 (-3.88%)

This chart shows the closing price for PTN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Palatin Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PTN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PTN

Analyst Price Target is $3.00
▲ +506.06% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Palatin Technologies in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 506.06% upside from the last price of $0.50.

This chart shows the closing price for PTN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Palatin Technologies. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/12/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/12/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/10/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/7/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/6/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/5/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/18/2021Canaccord GenuityReiterated RatingBuy$3.00
5/12/2020HC WainwrightReiterated RatingBuy$2.00
1/10/2020HC WainwrightLower Price TargetBuy$7.50 ➝ $2.00
11/13/2019HC WainwrightReiterated RatingBuy$7.50
9/13/2019Canaccord GenuitySet Price TargetBuy$6.00
9/13/2019HC WainwrightSet Price TargetBuy$8.00
6/24/2019HC WainwrightSet Price TargetBuy$8.00
5/23/2019LADENBURG THALM/SH SHSet Price TargetBuy$3.00
5/23/2019HC WainwrightSet Price TargetBuy$6.00
5/12/2019LADENBURG THALM/SH SHReiterated RatingBuy$2.75
5/9/2019HC WainwrightBoost Price TargetBuy$5.00 ➝ $6.00
1/11/2019HC WainwrightReiterated RatingBuy$5.00
11/14/2018HC WainwrightSet Price TargetBuy$5.00
9/13/2018HC WainwrightSet Price TargetBuy$5.00
6/27/2018LADENBURG THALM/SH SHInitiated CoverageBuy$3.00
6/4/2018HC WainwrightSet Price TargetBuy$5.00
5/15/2018HC WainwrightSet Price TargetBuy$5.00
4/6/2018HC WainwrightReiterated RatingBuy
4/6/2018HC WainwrightInitiated CoverageBuy$5.00
11/13/2017Canaccord GenuitySet Price TargetBuy$6.00
10/29/2017Roth CapitalSet Price TargetBuy$2.00
9/10/2017Canaccord GenuitySet Price TargetBuy$6.00
6/1/2017Canaccord GenuityReiterated RatingBuy$6.00
5/16/2017Canaccord GenuitySet Price TargetBuy$6.00
2/11/2017Canaccord GenuitySet Price TargetBuy$6.00
1/25/2017Roth CapitalReiterated RatingBuy$1.50
1/24/2017Roth CapitalReiterated RatingBuy
11/18/2016Roth CapitalReiterated RatingBuy$7.00
11/4/2016Roth CapitalReiterated RatingBuy$4.00 ➝ $7.00
11/2/2016Canaccord GenuitySet Price TargetBuy$6.00
9/23/2016Roth CapitalReiterated RatingBuy$4.00
9/22/2016S&P Equity ResearchLower Price Target$0.61 ➝ $0.55
9/20/2016Canaccord GenuitySet Price TargetBuy$6.00
9/9/2016Roth CapitalReiterated RatingBuy$4.00
(Data available from 8/5/2016 forward)
Palatin Technologies logo
Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis and COVID-19. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was founded in 1986 and is based in Cranbury, New Jersey.
Read More

Today's Range

Now: $0.50
Low: $0.50
High: $0.51

50 Day Range

MA: $0.48
Low: $0.38
High: $0.78

52 Week Range

Now: $0.50
Low: $0.38
High: $1.30

Volume

1,403,767 shs

Average Volume

3,630,814 shs

Market Capitalization

$113.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Palatin Technologies?

The following Wall Street sell-side analysts have issued research reports on Palatin Technologies in the last twelve months: Canaccord Genuity, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for PTN.

What is the current price target for Palatin Technologies?

1 Wall Street analysts have set twelve-month price targets for Palatin Technologies in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 506.1%. Canaccord Genuity has the highest price target set, predicting PTN will reach $3.00 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $3.00 for Palatin Technologies in the next year.
View the latest price targets for PTN.

What is the current consensus analyst rating for Palatin Technologies?

Palatin Technologies currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PTN will outperform the market and that investors should add to their positions of Palatin Technologies.
View the latest ratings for PTN.

What other companies compete with Palatin Technologies?

How do I contact Palatin Technologies' investor relations team?

Palatin Technologies' physical mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company's listed phone number is +1-609-4952200 and its investor relations email address is [email protected] The official website for Palatin Technologies is www.palatin.com.